{'fraction_non_alphanumeric': 0.024291497975708502, 'fraction_numerical': 0.001349527665317139, 'mean_word_length': 6.134615384615385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years

To assess the course of cancer‐free survival and thus determine how reliably reverse transcriptase‐polymerase chain reaction (RT‐PCR) can detect prostate‐specific antigen (PSA)‐expressing cells, as patients with untreated lymph node‐positive prostate cancer tend to have a poor prognosis, whereas those treated with radical prostatectomy (RP) and immediate adjuvant hormonal therapy show excellent local disease control and a disease‐free survival comparable with that of patients with negative lymph nodes, but the detection of micrometastatic disease in pelvic lymph nodes remains a major challenge.